Re: Bhide AA et al. Bladder contractility index changes with short-term antimuscarinic therapy in patients with detrusor overactivity: A placebo controlled randomised study

被引：0

作者：

Valdevenito, Juan Pablo ^{[1
]}

Olea, Mauricio ^{[1
]}

Mercado-Campero, Alejandro ^{[1
]}

机构：

[1] Hosp Clin Univ Chile, Dept Urol, Dr Carlos Lorca Tobar 999, Santiago, Chile

来源：

CONTINENCE | 2024年 / 9卷

关键词：

Antimuscarinics; Detrusor contractility; Urodynamics; FLOW;

D O I：

10.1016/j.cont.2023.101064

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：2

共 50 条

[41] "Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial." D. Stolz, E. Papakonstantinou, M. Pascarella, et al. Eur Respir J (vol 62, 2300218, 2023)
Stolz, D.
Papakonstantinou, E.
Pascarella, M.
EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (04)
[42] Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60
Safiri, Saeid
Ayubi, Erfan
EUROPEAN UROLOGY, 2017, 72 (03) : E63 - E63
[43] Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Garg, Harshit
Nayak, Brusabhanu
Singh, Prabhjot
EUROPEAN UROLOGY, 2019, 75 (02) : E25 - E25
[44] Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Poletajew, Slawomir
Radziszewski, Piotr
Palou, Juan
EUROPEAN UROLOGY, 2017, 71 (01) : E29 - E30
[45] Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9
Gratzke, Christian
Siddiqui, Emad
EUROPEAN UROLOGY, 2019, 75 (03) : E59 - E60
[46] Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive Lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol. 2016;10(5):1091-1097
Athyros, Vasilios G.
Papageorgiou, Athanasios
Athyrou, Valasia
Karagiannis, Asterios
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (01) : 306 - 307
[47] Re: Katharina Bruck, Richard P. Meijer, Joost L. Boormans, et al. Disease-free Survival of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy Versus Bladder-preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys. In press. https://doi.org/10.1016/j.ijrobp.2023.07.027
Basile, Giuseppe
Pradere, Benjamin
Lenfant, Louis
Seisen, Thomas
Roupret, Morgan
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 637 - 638
[48] Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8
Huddart, Robert
Hall, Emma
Lewis, Rebecca
Porta, Nuria
Hussain, Syed A.
James, Nicholas D.
EUROPEAN UROLOGY, 2020, 77 (06) : E156 - E157
[49] Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Arends, Tom J. H.
Witjes, J. Alfred
EUROPEAN UROLOGY, 2019, 75 (02) : E26 - E26
[50] Reply to Slawomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohy-perthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Arends, Tom J. H.
Witjes, J. Alfred
EUROPEAN UROLOGY, 2017, 71 (01) : E31 - E32

← 1 2 3 4 5 →